NYSE

Updated Oct 30, 7:59 PM ET

BHVN

Biohaven Ltd.

−$1.07 (6.49%) Fri · Closed $15.42

$0.00 (0.00%) ☾ After Hours

Oct 30, 7:59 PM ET

About BHVN

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

Cylvex Score

Weak

Significant risk exposure across axes

Multi-factor score. Not a buy/sell signal.

Score history

Calibrating

Score history is calibrating — it appears once enough daily scores are recorded.

What goes into the score

6 axes · equal weight
AnalystWall Street consensus & target distance
GrowthEarnings growth trajectory
ProfitabilityROE, margins, cash generation
ValuationPE, PEG, price-to-book ratios
TechnicalsPrice momentum & 52-week position
RiskBeta, volatility, leverage

The Cylvex Score is a multi-factor summary for education. Not a buy/sell signal. Not investment advice.